sur INNATE PHARMA (EPA:IPH)
Innate Pharma announces a conference on its half-year results
Innate Pharma, listed on Euronext Paris and Nasdaq, will hold a conference call on September 17, 2026. This event, scheduled for 2:00 p.m. CEST, will aim to present the company's financial results and business for the first half of 2026.
The presentation, led by Jonathan Dickinson and three other executives, will be accessible via webcast and conference call, links to which are available on the company's website. This broadcast will be archived for 90 days.
Innate Pharma, located in Marseille, is dedicated to the development of immunotherapies for cancer. Its portfolio includes the development of therapeutic antibodies, as well as several projects in partnership with companies such as Sobi and AstraZeneca.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INNATE PHARMA